



Christopher T Chen, MD

Assistant Professor of Medicine (Oncology)

Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

875 Blake Wilbur Dr Clinic E

Stanford, CA 94305

Tel (650) 725-5421 Fax (650) 723-8748

Bio

BIO

Dr. Chen is board-certified, fellowship-trained physician in oncology and hematology. He is also an Assistant Professor in the Division of Oncology in the Department of Medicine at Stanford University School of Medicine.

Dr. Chen attended Harvard College, where he graduated summa cum laude and Phi Beta Kappa in molecular biology. He went to medical school at Washington University in St. Louis on a full-tuition merit scholarship, graduating with Alpha Omega Alpha honors, and did his residency training in internal medicine at Massachusetts General Hospital and hematology/oncology fellowship in the Harvard Dana-Farber Cancer Institute/Massachusetts General Hospital program.

Dr. Chen is a member of the American Society of Clinical Oncology, European Society for Medical Oncology, and American Association for Cancer Research.

CLINICAL FOCUS

- Developmental Therapeutics
- GI Oncology
- Medical Oncology

ACADEMIC APPOINTMENTS

- Assistant Professor - University Medical Line, Medicine - Oncology
- Member, SPARK at Stanford

ADMINISTRATIVE APPOINTMENTS

- Director, Early Drug Development, Stanford Cancer Institute, (2023-2026)
- Clinical Director, Early Drug Development, Stanford Cancer Institute, (2021-2023)
- Team Science Division Representative, Department of Medicine, (2022- present)

HONORS AND AWARDS

- Weill Cancer Hub West Investigator, Weill Cancer Hub West (2026-2027)
- ISP Star Award, Stanford Medicine (2023)
- Shmunis Family Innovation Award in Cancer Therapeutics, Stanford Cancer Institute (2022-2023)
- Andrea Lynn Scott Memorial Research Fellowship, Cholangiocarcinoma Foundation (2021-2022)
- FDA-AACR Oncology Education Fellow, FDA / AACR (2020-2021)
- T32 Ruth L. Kirschstein-National Service Research Award in Cancer Biology, NIH (2018-2020)

PROFESSIONAL EDUCATION

- Medical Education: Washington University in St Louis School of Medicine (2014) MO
- Board Certification: Medical Oncology, American Board of Internal Medicine (2020)
- Board Certification: Hematology, American Board of Internal Medicine (2020)
- Board Certification, American Board of Internal Medicine , Medical Oncology (2020)
- Fellowship: Dana Farber Cancer Institute Hematology Oncology Fellowship (2020) MA
- Board Certification: Internal Medicine, American Board of Internal Medicine (2017)
- Residency: Massachusetts General Hospital Internal Medicine Residency (2017) MA
- BA, Harvard College , Molecular Biology, Economics, Health Policy (2010)

Research & Scholarship

CLINICAL TRIALS

- A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors, Recruiting
- A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2, Recruiting
- Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors, Recruiting
- Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors, Recruiting
- Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors, Recruiting
- A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers, Not Recruiting
- A Study of PY314 in Subjects With Advanced Solid Tumors, Not Recruiting
- Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder, Not Recruiting
- Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors, Not Recruiting
- Milademetan in Advanced/Metastatic Solid Tumors, Not Recruiting
- Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors, Not Recruiting
- Study of ADCT-301 in Patients With Selected Advanced Solid Tumors, Not Recruiting
- Study of ORIC-101 in Combination With Anticancer Therapy, Not Recruiting

Publications

PUBLICATIONS

- **Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.** *Nature communications*
Manabe, T., Bergo, H. C., Li, Q., Wang, T. S., Severson, P., Miller, N., Lee, C., Yay Donderici, E., Zhang, N., Wu, W., Chou, Y. T., Kerr, D. L., Allegakoen, et al

2026

- **Inferring optimal detection of *MTAP* homozygous loss (homozygous deletion) in gastric cancer: Associations with treatment exposure, disease site, and clinical outcomes.**
Staszewski, H., Cortez, E., Li, G., Danziger, N., Graf, R. P., Ross, J. S., Li, J., Risch, Z., Chen, C. T., Cohen, D. J.
LIPPINCOTT WILLIAMS & WILKINS.2026: 327
- **Phase I Clinical Trial Evaluating Safety, Tolerability, and Early Activity of Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF-Altered Solid Tumors or NRAS-Mutant Melanoma** *JCO Oncology Advances*
Gambardella, V., et al
2026
- **Phase 1 Study of [177Lu]Lu-NeoB in Patients with Advanced Solid Tumors Overexpressing Gastrin-Releasing Peptide Receptor: Preliminary Safety and Dosimetry Results.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
Mitra, E. S., Solnes, L. B., van der Veldt, A. A., Wong, J., Aloj, L., Heinrich, M. C., Chen, C. T., Rowe, S. P., Brabander, T., Pacey, S., Aimone, P., Pathak, D., Blumenstein, et al
2025
- **p53 drives lung cancer regression through a TSC2/TFEB-dependent senescence program.** *Cancer discovery*
Wang, M., Biegging-Rolett, K. T., Kaiser, A. M., Brady, C. A., Lockhart, J. H., Ferreira, S., Nguyen, K. T., Rajeevan, A., Evans, S. A., Zhao, T., Raj, N., Elkrief, A., Tischfield, et al
2025
- **Durable response to an anti-CD25 antibody-drug conjugate and anti-PD-1 antibody in ovarian carcinoma: a case report.** *Immunotherapy*
Bekheet, F., Ashland, M., Reyes, R., Dorigo, O., Karam, A., Chen, C. T.
2025: 1-5
- **Immunotherapy Efficacy in Mismatch Repair-Proficient Colorectal Cancer Patients With and Without Liver Metastases.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Beiter, E. R., Patel, S. R., Chen, C. T.
2025: JCO2501044
- **Milademetan in advanced solid tumors with MDM2 amplification and wild-type TP53: pre-clinical and phase 2 clinical trial results.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Dumbrava, E. E., Stinchcombe, T. E., Gounder, M., Cote, G. M., Hanna, G. J., Sumrall, B., Wise-Draper, T. M., Kanaan, M., Duffy, S., Sumey, C., Cobb, P., Forbes, A., Beckmann, et al
2025
- **Completed phase 1a dose escalation study of the first oral ENPP1 inhibitor RBS2418 immunotherapy in subjects with metastatic solid tumors.**
Marron, T., Wainberg, Z. A., Spira, A. I., Gordon, M. S., Chen, C. T., Segar, J., Scott, A. J., Boccia, R. V., Johnson, D. H., Berlin, J., Ho, W., Schanzer, J., Sengupta, et al
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Leveraging advanced practice providers in a clinical research program to provide trial prescreening and counseling increases clinic volume and trial accruals.**
Reyes, R., Arrieta, K., Shah, D., Janchenko, L., Chen, C. T., Breudecheck, K.
LIPPINCOTT WILLIAMS & WILKINS.2025: e13529
- **Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX): Two-Year primary outcome analysis.** *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*
Klebaner, D., Brown, E., Fisher, G. A., Shelton, A., Johnson, T. P., Shaheen, S., Chen, C., Heestand, G., Holden, T., Bien, J., King, D. A., Dawes, A. J., Morris, et al
2025; 207: 110884
- **Unveiling the Anti-Tumor Activity of Exarafenib in BRAF-Mutated NSCLC Through Genomic Analysis and Combined Preclinical, Clinical Outcomes**
Manabe, T., Wang, T., Severson, P., Miller, N., Lee, C., Donderici, E., Zhang, N., Bergo, H. C., Chou, Y., Kerr, D. L., Wu, W., Grandinetti, K. B., Soroceanu, et al
ELSEVIER SCIENCE INC.2025: S1-S2
- **Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.** *The New England journal of medicine*

- Schram, A. M., Goto, K., Kim, D. W., Macarulla, T., Hollebecque, A., O'Reilly, E. M., Ou, S. I., Rodon, J., Rha, S. Y., Nishino, K., Duruisseaux, M., Park, J. O., Neuzillet, et al
2025; 392 (6): 566-576
- **MDM2 inhibition is associated with the emergence of TP53-altered clonal hematopoiesis.** *NPJ precision oncology*
Khanna, V., Eslami, G., Reyes, R., Diep, R., Fernandez-Pol, S., Stehr, H., Suarez, C. J., Pinto, H., Ford, J. M., Zhang, T. Y., Chen, C. T.
2025; 9 (1): 34
 - **Unveiling Exarafenib's Role in BRAF-Mutated NSCLC Through Genomic Analysis and Combined Preclinical, Clinical Outcomes**
Manabe, T., Severson, P., Wang, T., Miller, N., Zhang, N., Donderici, E., Soroceanu, L., Lee, C., Pelham, R., Chou, Y., Khanna, V., Neal, J., Chen, et al
WILEY.2025: 1293
 - **A Model for Decoding Resistance in Precision Oncology: Acquired Resistance to FGFR inhibitors in Cholangiocarcinoma.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Goyal, L., DiToro, D., Facchinetti, F., Martin, E. E., Peng, P., Baiev, I., Iyer, R., Maurer, J., Reyes, S., Zhang, K., Majeed, U., Berchuck, J. E., Chen, et al
2024
 - **Redefining Available Therapy in Oncology Accelerated Approval Decisions.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Patel, S. R., Ramachandran, M., Ai, A., Chen, C. T.
2024: JCO2400892
 - **NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2024.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Ness, R. M., Llor, X., Abbass, M. A., Bishu, S., Chen, C. T., Cooper, G., Early, D. S., Friedman, M., Fudman, D., Giardiello, F. M., Glaser, K., Gurudu, S., Hall, et al
2024; 22 (7): 438-446
 - **ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors.** *Cancer research communications*
Chen, C. T., Khanna, V., Kummar, S., Abdul-Karim, R. M., Sommerhalder, D., Tolcher, A. W., Ueno, N. T., Davis, S. L., Orr, D. W., Hamilton, E., Patel, M. R., Spira, A. I., Jauhari, et al
2024
 - **Reflections and Roadmaps: Career Development Beyond the FDA-AACR Oncology Educational Fellowship.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Patel, T., Chen, C., Al Hadidi, S., Kadry, Y., Sridhara, R., Purcell, E., Wisch, L., Retzlaff, J., Foti, M., Pazdur, R., Kluetz, P., Gao, J.
2024
 - **Correlation of baseline ENPP1 and cGAS expression in advanced solid tumors with intratumoral immune activation and clinical outcomes after treatment with the first-in-class oral ENPP1 inhibitor RBS2418, alone or in combination with pembrolizumab**
Marron, T., Wainberg, Z. A., Spira, A. I., Gordon, M. S., Chen, C., Segar, J., Boccia, R. V., Berlin, J., Csiki, I., Schanzer, J., Huang, N., Glen, J., Klumpp, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
 - **Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) plus +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd)**
Pegram, M. D., Calfa, C., Chen, C., Salgado, A., Heeke, A., Kang, I., Pistilli, B., Pohlmann, P. R., Rugo, H. S., Saura, C., Vicier, C., Pearson, C., Mangeshkar, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
 - **A phase 1/2 study of BDC-3042, a novel dectin-2 agonistic antibody, in patients with advanced cancers.**
Salkeni, M., Vandross, A. L., Dumbrava, E., Giordano, A., Chen, C., Kenkel, J., Cai, D., Xu, L., Alonso, M. N., Ackerman, S., Yu, T., Colburn, D. E., Perez, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
 - **Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX).**
Pollom, E. L., Fisher, G. A., Shelton, A., Johnson, T., Chen, C., Jackson, S., Shaheen, S., Holden, T., Bien, J., King, D., Morris, A. M., Kin, C., Dawes, et al
LIPPINCOTT WILLIAMS & WILKINS.2024

- **A phase 1, open-label, dose escalation, and expansion study of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein, in patients with HLA-A*0201-positive disease and WT1-positive recurrent/metastatic cancers**
Uboha, N., Saenger, Y. M., Alese, O. B., Kim, D., Zheng, L., Chaves, J., Fu, S., Gong, J., Jin, Z., Powderly, J. D., Gabrail, N., Bekaii-Saab, T. S., Alistar, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Toward Precision Perioperative Therapy in GI Malignancies.** *JCO precision oncology*
Glover, M. J., Bien, J., Chen, C. T.
2023; 7: e2200381
- **Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.** *The Lancet. Oncology*
Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., Fountzilas, C., Kardosh, A., Kasi, et al
2023; 24 (5): 496-508
- **Trials in progress: a global phase 1/1b clinical trial evaluating exarafenib (KIN-2787), a highly selective pan-RAF inhibitor, in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma**
Spira, A., Gambardella, V., Kato, S., Perez, C., Mckean, M., Cao, M., Kim, R., Chen, C. T., Italiano, A., Cassier, P., Mehnert, J., Chmielowski, B., Lee, et al
AMER ASSOC CANCER RESEARCH.2023
- **GLIMMER-01: initial results from a phase 1 dose escalation trial of a first-in-class bi-sialidase (E-602) in solid tumors**
Luke, J. J., Johnson, M., Tolcher, A., Chen, C. T., Dai, T., Curti, B. D., El-Khoueiry, A., Sznol, M., Henick, B. S., Horak, C., Jayaraman, P., Cole, C. B., Wilson, et al
AMER ASSOC CANCER RESEARCH.2023
- **Results of a phase 1 study investigating camidanlumab tesirine as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors**
Chen, C.
2023
- **A PHASE 1/2 DOSE ESCALATION/EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF E-602, A BI-SIALIDASE FUSION PROTEIN, IN ADVANCED CANCER (GLIMMER-01)**
Sharma, M., Lathers, D., Johnson, M., Luke, J., Puzanov, I., Curti, B., Chen, C., El-Khoueiry, A., Henick, B., Callahan, M., Sznol, M., Patel, S., Wilson, et al
BMJ PUBLISHING GROUP.2022: A803
- **The Clinical Landscape of Cell-Free DNA Alterations in 1,671 Patients with Advanced Biliary Tract Cancer.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Berchuck, J. E., Facchinetti, F., DiToro, D. F., Baiev, I., Majeed, U., Reyes, S., Chen, C., Zhang, K., Sharman, R., Junior, P. L., Maurer, J., Shroff, R. T., Pritchard, et al
2022
- **Rectosigmoid Cancer-Rectal Cancer or Sigmoid Cancer?** *American journal of clinical oncology*
Hui, C., Baclay, R., Liu, K., Sandhu, N., Loo, P., von Eyben, R., Chen, C., Sheth, V., Vitzthum, L., Chang, D., Pollom, E.
2022
- **Phase 1b/2 trial of tucatinib plus trastuzumab plus /- chemotherapy or pembrolizumab in patients with metastatic HER2+GI cancers**
Shitara, K., Park, H., Bekaii-Saab, T., Kim, S. S., Kamath, S., Pishvaian, M. J., Chen, C., Zhen, D. B., Mayor, J., Tan, Q., Strickler, J. H.
ELSEVIER.2022: S502
- **Effect of camidanlumab tesirine (Cami) as monotherapy and in combination with pembrolizumab (PEM) on the immune cell profile in patients with selected advanced solid tumors**
Puzanov, I., Chen, C. T., LoRusso, P., Papadopoulos, K. P., Kummar, S., Hamilton, E., LeBruchec, Y., Havenith, K., Pantano, S., Toukam, M., Wuerthner, J., Boni, J.
AMER ASSOC CANCER RESEARCH.2022
- **Chromatin modifier alterations confer resistance to endocrine deprivation and CDK4/6 inhibitors in ER plus breast cancer and drive convergent evolution in patient autopsy lesions**
Leshchiner, E., Leshchiner, I., Martin, E. E., Chen, C. T., Zhang, T., Pinto, C., Rhissorakrai, K., Utro, F., Levovitz, C., Jacobs, R. A., Danysh, B. P., Slowik, K., Broudo, et al

AMER ASSOC CANCER RESEARCH.2022

- **A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2)**
Dumbrava, E., Hanna, G. J., Cote, G., Stinchcombe, T., Johnson, M., Chen, C., Devarakonda, S., Shah, N., Xu, F., Doebele, R., Gounder, M. M. LIPPINCOTT WILLIAMS & WILKINS.2022
- **Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy.** *JCO precision oncology*
Stamou, M. I., Chen, C., Wander, S. A., Supko, J. G., Juric, D., Bardia, A., Wexler, D. J. 2022; 6: e2100428
- **A Novel Framework for the Next Generation of Precision Oncology Targets.** *JAMA oncology*
Chen, C. T., Ford, J. M. 2022
- **Phase II trial of organ preservation program using short-course radiation and folfoxiri for rectal cancer (SHORT-FOX)**
Pollom, E. L., Shelton, A., Fisher, G. A., Bien, J., King, D., Johnson, T., Chen, C., Shaheen, S., Chong, C., Vitzthum, L., Kirilcuk, N., Morris, A. M., Kin, et al LIPPINCOTT WILLIAMS & WILKINS.2022
- **Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+gastrointestinal cancers (trial in progress)**
Park, H., Bekaii-Saab, T. S., Kim, S. S., Kamath, S., Pishvaian, M. J., Chen, C., Zhen, D., Mayor, J., Tan, Q., Strickler, J. H. LIPPINCOTT WILLIAMS & WILKINS.2022
- **Proteogenomic characterization of CDK4/6 inhibitor-resistant ER plus breast cancer**
Chen, C. T., Leshchiner, I., Martin, L., Kane, H., Rhrissorakrai, K., Utro, F., Levovitz, C., Gillette, M., Satpathy, S., Pinto, C., McLoughlin, D., Allen, R., Danysh, et al AMER ASSOC CANCER RESEARCH.2021
- **Paving a pathway for drug development in HER2-positive biliary tract cancer.** *The Lancet. Oncology*
Chen, C. T., Goyal, L. 2021; 22 (9): 1204-1206
- **A phase 1b, open-label, dose-escalation study to evaluate camidanlumab tesirine (Cami) as monotherapy in patients (pts) with advanced solid tumors.**
Puzanov, I., LoRusso, P., Papadopoulos, K. P., Chen, C. T., LeBruchec, Y., He, X., Cousin, T., Havenith, K., Boni, J., Bendell, J. C. LIPPINCOTT WILLIAMS & WILKINS.2021
- **Case 8-2021: A 34-Year-Old Woman with Cholangiocarcinoma.** *The New England journal of medicine*
Goyal, L. n., Chen, C. T., Pierce, T. T., Deshpande, V. n. 2021; 384 (11): 1054-64
- **Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer.** *Nature communications*
Pereira, B., Chen, C. T., Goyal, L., Walmsley, C., Pinto, C. J., Baiev, I., Allen, R., Henderson, L., Saha, S., Reyes, S., Taylor, M. S., Fitzgerald, D. M., Broudo, et al 2021; 12 (1): 3199
- **Characterization of spatial and temporal heterogeneity of ER positive metastatic breast cancer using serial biopsies**
Allen, R. K., Pinto, C. J., Fitzgerald, D. M., Huynh, T. G., Chen, C. T., Juric, D. AMER ASSOC CANCER RESEARCH.2020
- **Plasma sequencing demonstrates that breast cancer patients have a higher prevalence of clonal and multiple PIK3CA mutations than other solid tumor patients**
Chen, C., Sahu, A., Price, K., Pinto, C., Allen, R., Wang, X., Szabolcs, A., Goyal, L., Ting, D., Liu, S., Juric, D. AMER ASSOC CANCER RESEARCH.2020
- **Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Chen, C. n., Di Bartolomeo, M. n., Corallo, S. n., Strickler, J. H., Goyal, L. n.

2020; 40: 161–73

- **Response rates and lesion-level progression patterns of solid tumor patients in an academic phase I program: implications for tumour heterogeneity**
Chen, C., Pinto, C., Walmsley, C., Allen, R., Muzikansky, A., Henderson, L., Broudo, M., Wolfgang, J., Fitzgerald, D. M., Hong, T., Juric, D.
OXFORD UNIV PRESS.2019
- **Pharmacological inhibition of β -catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells.** *Science advances*
Feng, M., Jin, J. Q., Xia, L., Xiao, T., Mei, S., Wang, X., Huang, X., Chen, J., Liu, M., Chen, C., Rafi, S., Zhu, A. X., Feng, et al
2019; 5 (5): eaau5240
- **Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Hwang, T. J., Franklin, J. M., Chen, C. T., Lauffenburger, J. C., Gyawali, B., Kesselheim, A. S., Darrow, J. J.
2018; 36 (18): 1805-1812
- **Medicare Spending for Breast, Prostate, Lung, and Colorectal Cancer Patients in the Year of Diagnosis and Year of Death.** *Health services research*
Chen, C. T., Li, L. n., Brooks, G. n., Hassett, M. n., Schrag, D. n.
2018; 53 (4): 2118–32
- **Walk-in clinics versus physician offices and emergency rooms for urgent care and chronic disease management.** *Cochrane database of systematic reviews*
Chen, C. E., Chen, C. T., Hu, J., Mehrotra, A.
2017; 2: CD011774-?
- **Journey of Generic Imatinib: A Case Study in Oncology Drug Pricing.** *Journal of oncology practice*
Chen, C. T., Kesselheim, A. S.
2017; 13 (6): 352–55
- **Transforming healthcare delivery: Why and how accountable care organizations must evolve.** *Journal of hospital medicine*
Chen, C. T., Ackerly, D. C., Gottlieb, G. n.
2016; 11 (9): 658–61
- **Disruptive innovation in academic medical centers: balancing accountable and academic care.** *Academic medicine : journal of the Association of American Medical Colleges*
Stein, D. n., Chen, C. n., Ackerly, D. C.
2015; 90 (5): 594–98
- **Readmission penalties and health insurance expansions: a dispatch from Massachusetts.** *Journal of hospital medicine*
Chen, C., Scheffler, G., Chandra, A.
2014; 9 (11): 681-7
- **Beyond ACOs and bundled payments: Medicare's shift toward accountability in fee-for-service.** *JAMA*
Chen, C. n., Ackerly, D. C.
2014; 311 (7): 673–74
- **Massachusetts' health care reform and emergency department utilization.** *The New England journal of medicine*
Chen, C., Scheffler, G., Chandra, A.
2011; 365 (12): e25